Trial Profile
WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMPARED TO DOCETAXEL IN PATIENTS WITH PRETREATED ADVANCED NSCLC: AN OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Topotecan (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- 14 Oct 2008 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 02 Sep 2005 New trial record.